comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 05:07:40 - browse：779

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Covid hospitalizations on the rise, Humana says

entertainment

WSS

Why an extreme heat and wildfire smoke combination can be so dangerous

How to protect patients from sexual assault

A new House health package & hospitals’ new site

Weighted lottery helped low

The 10 drugs up first for Medicare price negotiation

Listen: Biogen's potential pivot, & Illumina's next chapter

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

What does generative AI mean for health care? We asked experts

Providers still hesitate to prescribe buprenorphine, study finds

Jerome Adams on the need for new antivirals for Covid

AstraZeneca chief proposes a novel edit to the drug pricing bill

Hepatitis C has a cure — but many Americans still lack access to it

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Continuity nursing helped my family in our darkest PICU moments

Providers still hesitate to prescribe buprenorphine, study finds

As demand for Covid shots wanes, Moderna seeks its next success

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

explore

A double vaccine crisis is endangering millions of children

Listen: Biogen's potential pivot, & Illumina's next chapter

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

A double vaccine crisis is endangering millions of children

NIH nominee Bertagnolli will get October confirmation hearing

Wikipedia

focus

entertainment

entertainment